EMA Recommends Romvimza for Tenosynovial Giant Cell Tumor
The CHMP's recommendation was based on results from the phase 3 MOTION study, which enrolled adults with symptomatic, unresectable TGCT. In the study, the objective response rate at week 25 was 40% for patients treated with vimseltinib compared with 0% for patients receiving placebo, as measured by RECIST criteria. Patients also reported clinically meaningful improvements in stiffness, range of motion, physical function, and quality of life.
Romvimza will be available as 14 mg, 20 mg, and 30 mg capsules.
The drug's most common side effects include increased liver enzymes, periorbital edema, increased cholesterol, rash, increased creatinine, decreased neutrophils, fatigue, face edema, pruritus, peripheral edema, and hypertension.
The CHMP concluded that the benefits of Romvimza outweighed the risks in this patient population, fulfilling an unmet medical need in those for whom surgery is not a viable option.
Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published on the EMA website after the marketing authorization has been granted by the European Commission. Lead image: Dreamstime
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Phillipson ready to ‘redouble efforts' to cut down on absent pupils
Education Secretary Bridget Phillipson has vowed to 'rebouble efforts' to cut down on the number of children missing classes at schools. She said progress was beginning to be made, despite government figures which showed the number of children in England who missed at least half of their classes rose to nearly 150,000 in autumn last year. Writing in The Daily Telegraph, she reiterated that tackling classroom absences was a 'top priority'. 'Reversing the harmful attitudes towards school attendance will not happen overnight. But we are beginning to make progress,' Ms Phillipson wrote. 'Now is the time to redouble our efforts to get more children back through the school gates. 'It's where they learn the habits that will shape them throughout life. It's where the building blocks of a healthy society are laid.' The Department for Education (DfE) figures, released last week, showed 147,605 pupils were classed as severely absent – which means they missed at least 50% of possible school sessions – in the autumn term of 2024/25. That is compared to 142,487 in the autumn term of 2023/24. The DfE said research shows a decline in the number of pupils persistently absent 'is likely to improve severe absence' in time. It added that the rate of increase in severe absence is slowing down compared to the previous two years. Ms Phillipson said the Government had started to 'turn the tide' with more than five million more days spent in the classroom in the past year. She said children with special educational needs and disabilities (Send) in particular were missing chunks of time with plans to transform the Send system and expand mental health support in schools. Among other plans, she highlighted attendance and behaviour hubs being rolled out from September and 'intensive, personalised support' for more than 500 schools facing the biggest challenges. She called on parents and schools to play their part in ensuring children were spending more time in the classroom. 'We will only continue to drive absence down if we discharge our shared responsibility: parents… sending children to school, schools creating welcoming classrooms, and the Government providing support,' she said. 'That's how we build a brighter future for our children, and for our country too.' Paul Whiteman, general secretary at school leaders' union NAHT, described last week's attendance figures as 'another small step in the right direction'.
Medscape
2 hours ago
- Medscape
49-Year-Old Patient's Pleomorphic Breast Relapse in Weeks
A 49-year-old woman with a history of bilateral breast cancer (right breast, cT2cN0M0, clinical stage IIA; left breast, cT2cN1M0, clinical stage IIB) presented with local recurrence in the right breast. Following neoadjuvant chemotherapy, the patient achieved a partial pathologic response and underwent breast-conserving surgery with axillary lymph node dissection and radiotherapy. After 6 years and 7 months, local recurrence in the right breast was identified, and the patient subsequently underwent mastectomy. However, 4 weeks later, metastasis to the contralateral breast was detected. An additional 13 weeks later, metastatic pleural tumours occupied approximately 70% of the thoracic cavity. Only detailed pathologic analysis revealed the underlying diagnosis of pleomorphic breast carcinoma. Nobuyuki Takemoto, MD, from the Department of Breast and Thyroid Surgery at Japan Medical Alliance East Saitama General Hospital in Satte, Japan, and colleagues documented the extremely rare case. The Patient and Her History The patient visited the hospital complaining of swelling and erosion of the right nipple. Her medical history included bilateral breast cancer diagnosed more than 6 years earlier. The right-sided tumour was the nonluminal type (oestrogen and progesterone receptor positive; HER2 3+; Ki-67, 31%), and the left-sided tumour was luminal A-like (oestrogen and progesterone receptor positive; HER2-; Ki-67, < 5%). As neoadjuvant chemotherapy, four cycles of adriamycin and cyclophosphamide (60/600 mg/m²) every 3 weeks, followed by paclitaxel (80 mg/m²) and trastuzumab (loading dose 4 mg/kg, maintenance 2 mg/kg) weekly for 12 weeks, were administered. The patient achieved a clinical partial response on imaging. Bilateral breast-conserving surgery and axillary lymph node dissection were performed. The pathologic evaluation of the therapeutic effect was grade 1 (right: ypT1bypN0M0, ypstageI; left: ypT1cypN0[i+]M0, ypstageI). After radiotherapy (50 Gy in 25 fractions) of the residual mammary gland, trastuzumab (6 mg/kg) was administered. However, the patient requested to discontinue treatment after two courses. She was subsequently followed with endocrine therapy (tamoxifen). Six years and 7 months after the initial operation, local recurrence occurred. Findings and Diagnosis On admission, all vital signs were within normal limits. Physical examination, including inspection, auscultation, palpation, and percussion, showed no abnormalities. Routine laboratory test results were unremarkable. A CT revealed a swollen right nipple. and three stump cytology tests for erosion were negative, but the nipple itself showed a tendency to grow, so a core needle biopsy (CNB) was performed. Pathologic findings showed invasive carcinoma and suggested metaplastic carcinoma. As no metastases to other organs were found, a right mastectomy was performed. After chemotherapy with carboplatin, radiation therapy to the supraclavicular fossa was planned; however, 4 weeks after the operation, a round mass of approximately 1 cm was found in the left breast. CNB revealed a suspicious malignant metaplastic carcinoma. It was determined that there was a high possibility of metastasis to the contralateral side, and a left mastectomy was performed. However, 12 weeks later, a left pleural tumour and a right chest wall mass appeared. After another 13 weeks, the left thoracic cavity was occupied by almost 70% of the pleural mass, and the right chest wall mass grew to 10 cm in size. Furthermore, the white blood cell count rose rapidly to 98.8 × 103/µL, with 94.8% neutrophils, 2.5% lymphocytes, and 1.8% monocytes. Bone marrow metastasis was suspected, but bone marrow aspiration could not be performed due to the patient's poor general condition. The patient died 25 weeks after the diagnosis of local recurrence. Pathologic examination revealed a pleomorphic carcinoma (PC) transitioning from ductal carcinoma, with a subtype of triple-negative breast cancer. Immunohistochemical staining showed positive expression of AE1/3 (anti-pan cytokeratin), beta-catenin, E-cadherin, and vimentin. Staining was negative for CAM5.2 (cytokeratin), HMB45 (human melanoma black 45), and LCA (leukocyte common antigen). Discussion 'When a rapidly growing breast mass is encountered, it is necessary to consider PC as one of diagnostic candidate. Little research has been done on PC, particularly on diagnosis and therapy. Thus, further case accumulation and analyses are awaited to gain more insight on the characteristics of PC,' the authors wrote.
Bloomberg
2 hours ago
- Bloomberg
Novartis Gets Boost as Autoimmune Drug Suceeds in Key Trials
Novartis AG succeeded in treating a form of autoimmune disease in late-stage studies, offering a boost for the Swiss drugmaker's potential for treatments in the field. Ianalumab showed improvement in disease activity in patients with Sjögren's disease, according to a statement Monday. The drug candidate was well tolerated and demonstrated a favorable safety profile for the disease, which has very limited treatment options.
